Bharat Immunologicals & Biologicals

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524663
₹9.06
▼ -1.02 (-10.12%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
—/100
Weak
Valuation
—/100
Data unavailable
Momentum
3/100
Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Public Sector Undertaking (PSU) of the Government of India. Established in 1989 in Bulandshahar, Uttar Pradesh, BIBCOL manufactures oral polio vaccines (OPVs) and other immunisers. The company formulates over 12.5 crore doses of OPV and had aggregated revenues of ₹30.5 crore in fiscal 2006.

Source: Wikipedia

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-61.0
Free Cash Flow
Data unavailable.
EPS Growth (YoY)
-1250.00%
as of Dec. 31, 2022
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-80.74%
as of Dec. 31, 2022
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
1.57%
as of Dec. 31, 2022
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-1323.40%
as of Dec. 31, 2022
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
7.20%
as of Sept. 30, 2022
Industry median 14.05% (173 companies)
Current Ratio
Data unavailable (needs a filed half-yearly balance sheet).
Debt to Equity
Data unavailable (needs a filed half-yearly balance sheet).
Interest Coverage
-1.48
as of Dec. 31, 2022
Industry median 10.58 (182 companies)
Net Margin
-11.64%
as of Sept. 30, 2022
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-8.37%
as of Sept. 30, 2022
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-11.00%
as of Dec. 31, 2022
Industry median 12.41% (182 companies)
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

0 of 3 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 4 met
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-10.1%
Low 8.6200 · High 9.8700
1W return
-32.5%
Low 8.6200 · High 13.4500
1M return
-41.7%
Low 8.6200 · High 18.0000
52W return
-61.0%
Low 8.6200 · High 18.0000
Lifetime High ₹90.0000 (June 17, 2021)
Lifetime Low ₹5.6500 (Aug. 23, 2019)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
10.9
10D
12.2
20D
13.6
50D
17.5
100D
21.7
200D
27.5

Delivery and volume

Day avg. delivery
53.0%
Week avg. delivery
65.5%
Month avg. delivery
67.1%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

9.18
Pivot
First resistance9.75
Second resistance10.43
Third resistance11.00
First support8.50
Second support7.93
Third support7.25
Day RSI9.0
Day MFI6.1
Day MACD-1.91
Day MACD signal-1.64

Beta

1M1.31
3M1.13
1Y1.13
3Y1.01

Price change analysis

↓ -41.7%
Over 1 Month
LowHigh
8.6218.00
↓ -61.0%
Over 3 Months
LowHigh
8.6218.00
↓ -61.0%
Over 6 Months
LowHigh
8.6218.00
↓ -61.0%
Over 1 Year
LowHigh
8.6218.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (Dec. 31, 2022)
₹0 Cr
Net profit (Dec. 31, 2022)
₹-5 Cr
Basic EPS (Dec. 31, 2022)
₹-1.0800

Ranks #None of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Mar 2024
  • Promoter59.25%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 59.25% in Mar 2024 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
27 Mar 2025 ARVINDBHAI JETHABHAI MORI Bulk Buy 300,000 20.2500 BSE
27 Mar 2025 PRIYA MANAVADARIYA Bulk Sell 300,000 20.2500 BSE
7 Jan 2025 NK SECURITIES RESEARCH PVT. LTD. Bulk Buy 248,928 33.7400 BSE
7 Jan 2025 NK SECURITIES RESEARCH PVT. LTD. Bulk Sell 248,928 33.8000 BSE
6 Jan 2025 PRIYA MANAVADARIYA Bulk Buy 232,327 30.1000 BSE
27 Dec 2022 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Sell 340,168 44.4900 BSE
27 Dec 2022 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Buy 497,590 44.5000 BSE
23 Dec 2022 TOPGAIN FINANCE PRIVATE LIMITED Bulk Buy 220,559 44.1200 BSE
23 Dec 2022 TOPGAIN FINANCE PRIVATE LIMITED Bulk Sell 220,559 44.8500 BSE
7 Jun 2021 ALPHA LEON ENTERPRISES LLP Bulk Buy 5 61.0500 BSE

All bulk and block deals →

Corporate Announcements

All 1 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Company Update Bharat Immunologicals & Biologicals Corporation Ltd-$ - 524663 - Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Thin net profit margin (-11.6%)
  • Declining profit YoY (-1323.4%)

Opportunities

  • RSI in oversold territory (9.0) -- a technical rebound zone

Threats

  • Down 61.0% over the past year
  • Weak interest coverage (-1.5x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Bharat Immunologicals & Biologicals

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.